Purpose Androgen deprivation therapy (ADT) has broad application in the treatment of prostate cancer (PC) and is associated with numerous, debilitating adverse effects. Increasing use of ADT for PC, longer timeframe for treatment (increased uptake of PSA testing and earlier diagnosis), as well as improved survival and an ageing population, means patients can live for a considerable period of time on or after ADT, experiencing these adverse effects. A number of systematic reviews of adverse effects of ADT for PC exist; however, no single systematic review has previously examined the evidence for all adverse effects, including newer forms of ADT. Methods A systematic review of existing systematic reviews of ADT for PC was conducted (2010-February 2019), as per Cochrane guidelines, to identify the highest level of risk/incidence evidence available, supplemented by evidence drawn from individual studies where no systematic review existed. Results Incidence data was generated for 19 adverse effect subgroups, classified according to the common terminology criteria for adverse events (CTCAE). Conclusion Incidence of adverse effects provides valuable information for future burden of disease studies. This information can better guide clinical management to reduce symptoms for patients and assist patients to make more informed decisions about their treatment, potentially improving disease outcomes. It also highlights the importance of supportive care for PC patients receiving ADT and their carers. For analysts conducting economic evaluations, the inclusion of adverse effects in PC decision analytic models can provide more comprehensive and accurate information for decision makers.
Introduction
Since the advent of PSA testing in the 1990s, the rising incidence and burden of prostate cancer (PC) has been a cause for concern. Treatment options for men with PC are varied and depend on a number of factors such as expected survival, risk of progression, stage and grade of cancer at diagnosis, age and health of the patient, family history, personal preferences of the patient and adverse effects of treatment. Androgen deprivation therapy (ADT) suppresses the production of androgen, which fuels the growth of PC. It has broad application in the treatment of PC, and many types of ADT are currently in use in Australia (Table 1) . ADT is predominantly used for intermediate or higher risk disease as well as advanced and metastatic cancer. It is also maintained when cancer becomes castration resistant. In addition, it is used as neo-adjuvant, concurrent, and adjuvant therapy with prostatectomy and radiotherapy [1] [2] [3] [4] .
ADT for PC is associated with numerous and often debilitating adverse effects. The National Institute of Cancer defines an adverse effect as: "an unexpected medical problem that happens during treatment with a drug or other therapy.
Adverse effects may be mild, moderate, or severe, and may be caused by something other than the drug or therapy being given. Also called an adverse event." [5] . The increasing use of ADT for PC, the longer timeframe for treatment (an outcome of increased uptake of PSA testing and earlier diagnosis), as well as improved survival and an ageing population, means patients can live for a considerable period of time on, or after, ADT, experiencing these adverse effects [6] .
While much has been published on the adverse effects of ADT for PC in recent years, and a number of systematic reviews exist , some of these do not include current studies or newer ADTs. No single systematic review has previously comprehensively examined the evidence for all adverse effects. Characterising adverse effects is beneficial for several reasons. Firstly, incidence of adverse effects will provide valuable information for future burden of disease studies and better guide clinical management to reduce symptoms for patients. Secondly, in this era of shared decision-making, such information will assist patients to make more informed decisions about their treatment, thus facilitating compliance with their treatment plan and potentially improving disease outcomes. For analysts conducting economic evaluations, inclusion of adverse effect incidence in PC decision analytic models can provide more comprehensive and accurate information for decision makers. The purpose of this paper, therefore, is to systematically review the current literature on ADT for PC to identify the highest level available evidence of risk/incidence of common adverse effects. Given the nature of current evidence, this review will comprise a review of existing systematic reviews, supplemented where necessary by evidence drawn from individual studies.
Methods
Using an a priori defined protocol, this systematic review was conducted as per Cochrane guidelines [30] . In order to locate the most recent high-level evidence and not duplicate previous research, a systematic search was conducted as outlined below.
Identification-search strategy
A PRISMA compliant systematic search of the literature on the adverse effects of ADT for PC was conducted for the years 2010-February 2019) [30, 31] . Figure 1 shows the search process (identification, screening, eligibility and inclusion). The study screening and selection process consisted of three phases. First, a search was conducted to identify original articles in the following electronic databases: Medline, Embase, PsycInfo and Cochrane Library. The search strings comprised 
Classification of studies
Identified studies were then classified using a three-step process.
Step 1: Screening Titles and abstracts of the retrieved articles were screened following the PICOS criteria in Table 2 .
Step 2a: Classification of adverse effect groupings The remaining records were classified into adverse effect groupings using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [32] to enable comparison of available evidence for specific adverse effects (Table 3) .
Step 2b: Identifying highest level of evidence In order to have incidence data supported by the highest level of evidence available, classification of articles was guided by the Oxford Centre for Evidence-based Medicine (OECBM) 2011 Levels of Evidence [33, 34] . Studies were classified into (A) systematic reviews; (B) analytic studies, comprising (i) experimental studies such as RCTS and (ii) observational studies; and (C) descriptive studies. Systematic reviews were prioritised; where they did not provide the evidence required, RCTs were the next level of evidence included. Observational studies were maintained until step three, in the event that higher level studies did not address adverse effect incidence. Descriptive studies were excluded.
The full text versions of the remaining records were obtained and independently assessed for eligibility by two reviewers (KE and HT). Disagreements were resolved through consensus. Where studies of equal quality and evidence level were found, all results were recorded to strengthen the evidence collected. Remaining lower evidence articles were then excluded. The following exclusion criteria were applied with the benefit of full text information: not highest level of evidence available; no incidence information; more recent but equivalent evidence available. Finally, the reference lists of included studies were manually reviewed to identify articles not located by the electronic database search.
Data extraction
Data was extracted from the included studies by one reviewer (KE) and independently reviewed by a second reviewer (HT). For each study, information was recorded on first author, year and country where study was conducted; sample size and setting; study type, study outcomes or incidence data; and risk of bias or quality assessment.
Methodological quality of systematic reviews and single studies
Quality assessment of included systematic reviews was conducted using the AMSTAR 2, a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both [35] . Included individual studies were critically appraised using Cochrane Collaboration recommended tools ROB 2 [36] for RCTs and the Newcastle-Ottawa Scale (NOS) [37] for cohort studies [30, 38] . Risk of bias or quality ratings were independently assessed by KE and HT to address the possibility of rating error. Any discrepancies were addressed via consensus. Systematic reviews receiving a critically low rating were excluded from the evidence synthesis.
Analysis
Given that the purpose and characteristics of the included individual studies (sample populations, treatment types, PC stages, patient age, control groups, adverse effect examined and outcomes measured) varied considerably across studies, a meta-analysis was not appropriate for the purposes of this review. Instead, evidence of the highest level available was collected and compared for each adverse effect and a range of scores recorded to ensure the most rigorous incidence data was generated by this systematic review. Hepatobiliary disorders a) Hepatic disorders 2 (SR); 1 (IS) 7
Reproductive system disorders a) Gynaecomastia and breast pain 3 (SR) b) Sexual dysfunction 2 (SR); 2 (IS) 8
Psychiatric disorders a) Depression 2 (SR) 9
General disorders a) Fatigue 3 (SR) b) Gait disturbance 4 (IS)
SR systematic review, IS individual study, CTCAE Common Terminology Criteria for Adverse Events, NB Some studies have multiple adverse effect outcomes so may count more than once
Results
The search of databases located 1253 records. Google Scholar and a survey of reference lists generated a further six records (n = 1259). Thirty-one duplicates were removed electronically. A total of 1228 records remained for screening. After preliminary screening of titles and abstracts, 1110 studies that did not match the inclusion criteria were removed. A total of 118 studies remained. Thirty-two full text systematic reviews met the inclusion criteria and were evaluated for adverse effect incidence. Evidence was generated for incidence of body composition changes, bone loss, osteoporosis, metabolic syndrome, diabetes, hypertension, cardiovascular disease (CV) risk, thromboembolisms, hepatotoxicity, fatigue, body feminisation, vasomotor flushing, depression, cognitive function and dementia. The remaining single studies (n = 86) were then examined for evidence of adverse effect incidence not generated by the systematic reviews (osteoporosis, hepatotoxicity, gait disturbance, fracture, sexual function) ( Table 3 ). The highest level of evidence generating comprehensive data (e.g. including sufficient stages of PC and types of ADT) were included in the evidence synthesis for these adverse effects.
Thirty-nine studies (25 systematic reviews +14 individual studies) were judged eligible for inclusion in the review. Detailed information extracted from the 39 studies was recorded in the summary of findings table (Online Resource 2).
The following section examines each of the adverse effect sub groups in turn, summarising study characteristics and adverse effect incidence.
Musculoskeletal changes

Bone loss
ADT increases bone turnover and causes significant, progressive decrements in bone mineral density (BMD) in men with PC, contributing to an increased risk of osteoporosis and fractures. The magnitude of bone loss rates tends to be higher early in treatment but also decreases steadily during longterm treatment [39] . The extent of bone loss differs for measurement site and duration of ADT. One systematic review included five prospective cohort studies of localised or advanced PC treated with orchiectomy, luteinising hormone releasing hormone (LHRH) agonist or anti-androgen [13] . Controls varied across the studies as did treatment duration, with heterogeneity ranging from 82 to 99%. Pooled analysis of four studies (n = 483) determined mean percent bone loss for lumbar spine of − 3.6% (95% CI. -6.72, − 0.47, p = 0.02). Five studies (n = 515) recorded bone loss for femoral neck of − 3.11% (95% CI − 4.73, − 1.48, p = 0.02). Mean percent bone loss for total hip derived from four studies (n = 483) was − 1.59% (95% CI − 2.99, − 0.19, p = 0.03) [13] .
Osteoporosis ADT-induced bone loss is further exacerbated by already high levels of osteoporosis in the ageing population. Studies in UK [40] and US [41] have reported levels of around 40% for osteoporosis and between 40 and 50% for osteopenia in men with PCinitiating ADT. The risk of osteoporosis is heightened by age and comorbidities common in this population. One recent retrospective cohort study conducted in Australia using Pharmaceutical Benefits Scheme (PBS) data involved a 10% random sample of the PC population receiving their first ADT between 2004 and 2010 compared with a matched population not receiving anti-neoplastic agents or having no comorbidities at baseline [42] . There was significant risk of developing osteoporosis in the ADT PC population: hazard ratio (HR) 1.65 (95% CI 1.48, 1.85). An adjusted HR was also calculated for incidence of osteoporosis stratified by duration of ADT exposure ≤ 1 year 1.38 (95% CI 1.10, 1.72) and > 1 year 1.77 (1.55-2.02) [42] .
Fracture
Two RCTs and six cohort studies with data on incidence of fractures in men receiving ADT met the inclusion criteria for this review. Two studies focussed on localised PC; one included recipients of ADT alone, curative treatment and ADT, and orchiectomy [43] ; the other men received radical prostatectomy or radiotherapy with/without ADT [44] . Four studies focussed on advanced cancer, one included only men with non-metastatic PC receiving any type of ADT or orchiectomy [45] , another, men with metastatic PC comparing gonadotropin-releasing hormone (GnRH) agonists with orchiectomy [46] , the third, men with advanced cancer receiving intermittent ADT (IADT) [47] , and the fourth, men receiving GnRH agonists only with nonmetastatic or metastatic PC [48] . Two RCTs examined second generation treatments for non-metastatic [49] and metastatic castrate resistant PC (CRPC) [50] . These studies established a significant association between ADT and incidence of fracture across the disease spectrum, and identified factors that elevate risk such as age, ADT dose and duration, time from last dose, osteoporosis, metastases and dementia (Table 4 ).
Metabolic changes
Body composition changes
Body composition changes increase with duration of treatment and comorbidities; they tend to be greater in the first 3 months and continue over time but less rapidly to 6 months and longer [11] . A meta-analysis by Haseen et al. [11] reported significant changes in body composition for men receiving ADT. Pooled analysis was conducted from 16 studies (14 cohort and 2 RCTs) which varied in type of ADT and stage of PC. Analyses included seven studies for increases in body fat mass of 7.7% (95% CI 4.3, 11.2, p < 0.00001), six for decreases in lean mass of 2.8% (95% CI − 3.6, − 12.0, p < 0.00001), nine for increases in body weight of 2.1% (95% CI 1.35, 2.94, p < 0.00001) and eight for increases in body mass index (BMI) of 2.2% (95% CI 1.16, 3.14, p < 0.0001). Heterogeneity was quite high across the studies included for each body composition change, 99%, 73%, 55% and 63%, respectively. Sub-analyses for ADT type showed that luteinising hormone releasing hormone (LHRH) had greater impact on body composition changes than combination therapy with anti-androgen.
Metabolic syndrome
Men receiving ADT tend to experience adverse changes in the following metabolic features: decreased lean mass, increased fat mass (together known as sarcopenic obesity), increased waist circumference, alterations in lipids and decreased insulin sensitivity [51, 52] . One systematic review of ADT-induced metabolic syndrome incorporated data for meta-analysis from four cohort studies and five cross sectional studies [8] . The type of ADT varied across studies from any type of ADT in five studies, GnRH agonist, combined androgen blockade, orchiectomy and anti-androgens in one study and orchiectomy alone in two. The relative risk (RR) of acquiring metabolic syndrome was 75% higher for men with PC receiving ADT compared with those not receiving ADT (RR 1.75; 95% CI 1.27, 2.41) [8] .
Diabetes
Two systematic reviews generated data on diabetes incidence. The Bosco et al. [8] review mentioned above reported a RR of 1.36 (95% CI 1.17, 1.58) for men receiving ADT. Wang et al. [27] pooled data for meta-analysis from four cohort and four cross sectional studies. Incidence of diabetes among men HR hazard ratio, aHR adjusted hazard ratio, GnRHa gonadotropin releasing hormone agonists, IADT intermittent androgen deprivation therapy, CADT continuous androgen deprivation therapy; MO not metastatic, Met metastatic receiving ADT (GnRH agonists, combined androgen blockade or orchiectomy) was 10.9% [27] . The risk of diabetes was 39% higher for these men than for men not receiving ADT or men on watchful waiting or active surveillance (RR 1.39; 95%CI 1.27-1.53, P < 0.001) [27] . Sub-group analyses for ADT type and duration showed that GnRHa, combined androgen blockade and orchiectomy are significantly associated with risk of diabetes, and longer duration of ADT with elevated risk [27] .
Cardiac disorders: cardiovascular complications and mortality
Since a large observational analysis of Surveillance, Epidemiology and End Results (SEER) Medicare data demonstrated a significant association between GnRH and incident coronary heart disease, hospital admission for myocardial infarction (MI) and sudden cardiac death in men with PC; the question of whether ADT increases the risk of CV events or CV mortality has been raised [53] . A systematic review conducted in 2009 showed that ADT is associated with a 17% increased risk of cardiovascular mortality [54] . This analysis, however, was based on only two observational studies and two RCTs. Since that time, studies of CV risk for ADT recipients have proliferated, and systematic reviews have been conducted of CV risk factors such as hypertension, as well as CV events including MI and CV mortality. While the included systematic reviews focus on CV adverse events, the outcomes measured differ, as do type of ADT, stage of PC and comparators. Attempts were made to address heterogeneity via pooled meta-analyses, within trial analyses or analyses by study (Table 5 ).
There was an increased risk of CV mortality for all types of ADT and for MI or stroke from GnRH agonists, anti-androgens and orchiectomy combined. For ADT type, orchiectomy has the highest risk ratio and antiandrogens [7, 28] or IADT [12, 15] , the lowest risk compared with no ADT. The risk for CV events was similar across types of ADT and varied dependent largely on the comparator, as the study by Scailteux shows [24] . One systematic review found no significant differences in risk for CV mortality between ADT and controls across all included studies [21] . In other reviews, degarelix reduced the risk of CV events compared to GnRHa, as did IADT [12, 15, 25] . There was a strong association between grade 3 cardiac adverse events and grade 3/4 vascular events and arbiraterone acetate + prednisone compared to placebo [23] . This impact was lower for all grade events. The relative risk of CV events with enzalutamide was lower than that for abiraterone acetate [29, 55] .
Nervous system disorders
Cognitive impairment
Two systematic reviews examined incidence of cognitive impairment from ADT [16, 26] . Sun et al. [26] conducted a meta-analysis of six cohort studies; two of which were prospective and resulted in an odds ratio (OR) of 1.56 (0.50, 4.91, p = 0.441). The remaining four retrospective sub groups included men with senile dementia and Alzheimer's disease, and while the risk of cognitive impairment was higher, it was not statistically significant (HR 1.28; 95% CI 0.93, 1.76 p = 0.130). They concluded that results could not reliably confirm the relationship between ADT and cognitive impairment. A second metaanalysis of 14 studies suggested that for men receiving ADT for PC, there was insufficient evidence to support cognitive decline with the exception of compromised visuomotor skills, where a significant decline was reported. The weighted average effect was − 0.67 (95% CI − 1.17, − 0.17; P = 0.008) [16] . The extent of the deficit was also larger with shorter time to follow-up. However, there was insufficient evidence to determine whether these deficits were primarily motor related, that is arising from ADT-related muscle loss, or evidence of low testosterone related deficits in visuospatial skill. The authors concluded that ADT recipients can expect cognitive functioning to be similar to that of men with PC not receiving ADT and men without PC; however, clinicians and patients need to be aware of the potential for visuomotor impairment when deciding on treatment [16] .
Stroke
Two meta-analyses were conducted to determine incidence of stroke. Meng et al. [17] found a significant association between stroke and some types of ADT. Pooled analyses of GnRH alone resulted in a HR of 1.20 (95% CI 1.12, 1.28, P < 0.001); GnRH + anti-androgen, a HR of 1.23 (95% CI 1.13, 1.34, P < 0.001); and orchiectomy a HR of 1.37 (1.33-1.46, P < 0.001). The HR for all ADT showed a higher incidence for ADT recipients compared with control groups, (HR1.12; 95% CI 0.95, 1.32), but no significant association. Another meta-analysis conducted pooled analyses of a range of different types of ADT showing a significant association between stroke and ADT [24] . For example, in the only RCT, RR of GnRH agonist compared with GnRH antagonist was 3.44 (95% CI 0.22, 1.32). In observational studies, results varied considerably between different types of ADT with greater relative risk for GnRH agonists and orchiectomy compared with anti-androgens and combined androgen blockade (CAB) (Online Resource 2). 
Dementia
Men receiving ADT have increased circulating β-amyloid protein levels, the accumulation of which characterizes Alzheimer's disease [19] . Men diagnosed with dementia tend to have lower testosterone levels and impaired cognitive function, which for recipients of ADT, has been noted from as early as 6 months post-treatment initiation [19] . One systematic review conducted a meta-analysis of studies reporting any dementia outcome showed an increased risk associated with ADT (HR 1.47; 95% CI 1.08, 2.00; p = 0.02). Studies reporting all cause dementia and Alzheimer's disease were also analysed separately resulting in hazard ratios of 1.46 (95% CI 1.05-2.02; p < 0.001) and 1.25 (95% CI 0.99, 1.57; p < 0.06), respectively. Current evidence thus suggests that ADT may be associated with an increased risk of dementia [19] .
Vascular disorders
Hypertension Hypertension is one of the strongest risk factors for all CV diseases and is strongly associated with age. ADT, particularly second generation hormonal agents such as abiraterone acetate and enzalutamide, is associated with significant increases in risk of hypertension. Four systematic reviews generated data on the incidence of hypertension for men receiving ADT for PC [22, 29, 55, 56] . One showed a higher incidence of long-term hypertension with radiotherapy and GnRH agonists than with the use of anti-androgens (12% vs 4%) [56] . Abiraterone acetate and enzalutamide compared with placebo or other forms of ADT were associated with a high risk of hypertension, higher than that for CV events in three systematic reviews [22, 29, 55] (Online Resource 2). RCTs randomized controlled trials, OR odds ratio, AEs adverse effects
Thromboembolic events
Population-based studies of men receiving ADT for PC have revealed an association between ADT and increased risk of thromboembolic events such as deep vein thrombosis (DVT) and pulmonary embolus (PE). Two metaanalyses examined the evidence for ADT-associated thromboembolic events [10, 18] . One restricted the analysis to five cohort studies which compared GnRH agonists alone, GnRH agonists + anti-androgens, anti-androgens alone and orchiectomy with no ADT [10] . In this metaanalysis, DVT was significantly associated with GnRH agonist alone (HR 1.47; 95% CI 1.07, 2.03 p = 0.017), GnRH agonist + anti-androgen (HR 2.55; 95% CI 2.1, 2.94, p < 0.001) and anti-androgen alone (HR 1.49; 95% CI 1.13, 1.96, p = 0.004), but not with orchiectomy (HR 1.80 95% CI 0.93, 3.47, p = 0.07). Pulmonary embolism was significantly associated with GnRH agonist alone (HR 2.26; 95% CI 1.78, 2.86, p < 0.001) and orchiectomy (HR 2.12; 95% CI 1.44, 3.11, p < 0.001) [10] . The other systematic review included oestrogens in addition to the abovementioned forms of ADT and drew evidence from 20 studies comparing ADT with no ADT, short-term ADT and IADT [18] . In this meta-analysis, ADT without oestrogen in 10 studies caused a significant increase in risk of thromboembolic events (RR 1.43; 95% CI 1.15, 1.77, p < 0.001) as did oestrogen alone in 9 nine studies (RR 3.72; 95% CI 1.78, 7.80, p < 0.001). Sub-analyses comparing disease stage demonstrated a significantly increased risk of thromboembolic events from ADT without oestrogen and oestrogen alone for both localized (RR 1.10; 95% CI 1.05, 1.16, p = <0.001) and metastatic disease (RR 1.58; 95% CI 1.24, 2.03, p < 0.001), but not for studies of continuous vs intermittent ADT. Sub-analyses examining impact of ADT duration showed a significantly increased risk of thromboembolic events for duration > 12 months. Significant heterogeneity was resolved in ADT without oestrogen analysis for localized disease (0%) but not for the metastatic disease analysis (84%) or the oestrogen only analysis (71%) [18] .
Hot flashes
Five systematic reviews referred to incidence of vasomotor flushing across various treatments and stages of PC from locally advanced to metastatic CRPC [14, 15, 25, 29, 56] . Antiandrogens have a significantly lower risk of flashing than orchiectomy (RR 0.23; 95% CI 0.10, 0.27) [14] and GnRH agonists (< 1% vs 45%) [56] . Enzalutamide has a significantly increased risk of flashing compared to bicalutamide or placebo (RR 1.94; 95% CI 1.55, 2.42) [29] . There was no significant difference in flashing between CADT and IADT [15] or between degarelix and GnRH agonists [25] .
Hepatobiliary disorders
Two systematic reviews examined incidence of hepatotoxicity; one from ADT + abiraterone acetate + prednisone compared with placebo for metastatic hormone sensitive PC (HR 3.09; 95% CI 2.12, 4.50, P < 0.001) [23] , and one from abiraterone acetate + prednisone compared to placebo for CRPC (all grade RR 1.93; 95% CI 1.15, 3.24, p = 0.01 and high grade RR 2.94; 95% CI 0.95, 9.08, p = 0.06) [22] . A large population-based study (n = 82,938) using SEER-Medicare data for 1992-2009 found a significantly increased risk of any liver disease (HR 1.47, 95% CI 1.35, 1.60 
Reproductive system disorders
Gynaecomastia and breast pain
Gynaecomastia and breast pain are common adverse effects of non-steroidal anti-androgen therapy (bicalutamide, flutamide), and less so, GnRHa therapy, that can seriously impact men's masculinity and quality of life [9, 58] . Three systematic reviews analysed the incidence data [14, 15, 56] . Two studies reported that, compared with GnRH agonists, non-steroidal anti-androgen therapy was associated with a significantly increased risk of gynaecomastia (RR 8.43; 95% CI 3.19-22.28) [14] and 70% vs 11% [56] . One of these studies also reported a 23-fold increased risk of breast pain pooled from eight studies (RR 22.97; 95% CI 14.79, 35.67) [14] .
There was a lower risk of gynaecomastia for IADT compared to CADT (RR 0.63; 95% CI 0.36, 1.10), but the difference was not statistically significant [15] .
Sexual dysfunction
Sexual dysfunction, which here refers to erectile dysfunction and decreased libido, is a common and often distressing experience for both men receiving ADT for PC and their partners. Two systematic reviews included RCTs with incidence of sexual dysfunction or decreased libido, one comparing erectile dysfunction between degarelix and GnRH agonists (RR 0.94 95% CI 0.700, 1.26, p = 0.686) [25] , the other IADT and continuous CADT for erectile dysfunction (RR 1.03; 95% CI 0.74, 1.43) and decreased libido (RR 1.01; 95% CI 0.95, 1.07) [15] . No significant differences were found for erectile dysfunction or decreased libido between types of ADT. There is a paucity of data on sexual dysfunction; however, two RCTs which examined the effect of shortterm neoadjuvant ADT before radiotherapy and compared ADT recipients with those receiving radiation only, reported significant declines in sexual function from 2 months ADT administration [59, 60] . Daly et al. [59] compared duration of ADT; 54% of men in the 4-month arm and 39% in the 8month arm, who had sexual function at baseline, retained sexual function at 1 year. There were no statistically significant differences between arms and smaller decreases in sexual function were recorded after 1 year [59] . This study found that 26% of men can expect to retain erectile function 5 years after receiving 3 or 4 months of ADT with age the only significant risk factor [59] . Similar results were obtained in a second RCT comparing men receiving neoadjuvant ADT and radiotherapy and those receiving radiotherapy alone. There was a statistically significant difference between arms: number of men who always or almost always had erectile function at baseline in the ADT arm decreased by over 50% 1 year after ADT initiation [60] .
Psychiatric disorders: depression
Depression and anxiety are often unaddressed adverse effects among patients with PC and are associated with increased health service use, costs and mortality [61] [62] [63] . Two systematic reviews examined the incidence of depression among men with PC receiving ADT [15, 20] . One conducted a pooled analysis of 18 studies, both prospective and retrospective, involving a variety of forms of ADT from primary anti-androgen, radiotherapy or radical prostatectomy plus adjuvant ADT and orchiectomy. Comparators included lesser exposed ADT group (e.g. no ADT, short-term ADT or IADT). Relative risk of depression was 1.41 (95% CI 1.18-1.70, p < 0.001) [20] . The second systematic review analysed 15 RCTs of which three generated evidence of depression experienced by recipients of continuous and intermittent ADT and found no significant difference between IADT and CADT (RR 0.91; 95% CI 0.39, 2.13) [15] .
General disorders
Fatigue Three systematic reviews examined the incidence of fatigue for men receiving ADT for PC. One conducted a pooled analysis of all stages of PC and found no significant difference between IADT and CADT but an incidence of fatigue that favoured IADT (HR 0.94; 95% CI 0.60, 1.48) [15] . However, for men receiving new hormonal agent-based therapies for metastatic CRPC, enzalutamide or abiraterone acetate, fatigue is one of the most common adverse effects. A significant difference in incidence was discovered from pooled analyses of both all grade (RR 1.27; 95% CI 1.13, 1.43) and grade 3 or greater fatigue (RR 1.25; 95% CI 0.92, 1.71, p = 0.02) [64] . Similarly, Zhu et al. [29] reported a significantly higher incidence of fatigue with enzalutamide for all-grade adverse events (RR 1.29; 95% CI 1.17, 1.42) and high-grade adverse events (RR 1.50; 95% CI 1.08, 2.08).
Gait disturbance, physical function and falls
Clinically meaningful declines in physical functioning occur within 3-6 months after ADT initiation and stabilise or worsen over time [65] [66] [67] . Alibhai et al. [65] report that for each 5kg reduction in grip strength over 4 years, there was a 24% increased mortality risk, and with each 5% loss of relative grip strength, a 6% increased mortality risk. In a secondary analysis of this same population, the incidence of falls was higher for men receiving CADT, with a trend towards increased risk (p = 0.083) [68] . Graff et al. [69] conducted a sub-group analysis (≥ 75 years) of participants in the PREVAIL RCT, where there was a much higher incidence of falls, suggesting enzalutamide may further increase the risk of falls because all men in the trial were receiving ADT. In a phase III, double-blinded RCT examining apalutamide versus placebo, Smith found a higher incidence of falls for participants receiving apalutamide [49] (Online Resource 2).
Methodological quality of included studies
Systematic reviews
Twenty-five systematic reviews (24 incorporating a metaanalysis) were assessed using the AMSTAR 2 tool (Online Resource 3). Confidence in overall results of the review rating varied, 10 were rated as low, 11 as moderate, and four as high. Results were impacted by lack of data or diversity of studies available. ADT is used broadly across the spectrum of PC, so patient characteristics differ as do the type and duration of ADT administration. In addition, studies involved different comparators or control groups, making comparison across studies difficult. Heterogeneity between studies within reviews was often quite high. Risk of bias or quality assessments were not always conducted or just not reported in lower rated studies, despite their critical importance. Similarly, publication bias was overlooked in a number of reviews. Overall, systematic reviews brought together a comprehensive collection of the best available evidence on the adverse effects of ADT for PC and provide a sound evidence base.
Randomised controlled trials
Four RCTs were assessed for risk of bias using the ROB-2 tool generating ratings such as low, some concerns or high risk of bias (Online Resource 4). Three of the four trials rated an overall low risk of bias, and two of these were studies based on well-known trials (ICORG 97-01; PREVAIL); all four were published in high ranking journals by recognised authors/clinicians in the PC field; however, all four also had varying degrees of conflict of interest from author association with pharmaceutical companies.
Cohort studies
Ten cohort studies were assessed for quality using the Newcastle Ottawa Scale (NOS) for a possible rating of good, fair or poor (Online Resource 5). All achieved a rating of good, and only three had weaknesses which were not considered sufficient to require a downgrading, given their other strengths. One study had missing outcome data that was not addressed and no measures to prevent confounding from previous falls or exercise [68] ; another had a 40% loss to followup [65] and the third matched their experimental and control cohorts for age and no prior comorbidity only [42] .
Discussion
This comprehensive systematic review of adverse effects (n = 19) of ADT for PC confirms that many are commonly experienced by patients and survivors. A broad spectrum of ADT is represented, comprising GnRH agonists, GnRH antagonists, anti-androgens (steroidal and non-steroidal) and combinations of these drugs or neoadjuvant and adjuvant therapy with curative treatments like RP or RT. Intermittent ADT is also represented. Second generation non-steroidal anti-androgens, abiraterone acetate and enzalutamide, figured strongly in the systematic reviews. Statistically significant increased risks were evident in all the most common adverse effects from the CTCAE groupings (musculoskeletal, metabolic, cardiac, nervous system, vascular, hepatobiliary, reproductive system, psychiatric and general disorders). The dominant factor across all adverse effect incidence was type of ADT. For musculoskeletal events, duration of ADT was also a factor; for fractures, ADT dose, age, presence of osteoporosis, metastases and dementia impacted on incidence. ADT impacted combined CVD morbidity and the risk of specific CV diseases such as myocardial infarction and ischaemic heart disease. Risk was associated with type [7, 28] , adverse event grade [22, 23, 29] and duration of ADT [70] . Cardiac mortality was less common, but increased risk was identified for all ADT, ADT monotherapy and GnRH agonists [28] . Increased risk of stroke was associated with orchiectomy, CAB and GnRH agonist alone [17] . There was also a significant association between ADT and hypertension, particularly for second generation therapies, abiraterone and enzalutamide. Other vascular disorders like thromboembolic events also showed a significant association with GnRHa alone, CAB, antiandrogen alone, oestrogen and orchiectomy [10, 18] . For vasomotor flashing, enzalutamide had a significant increased risk and anti-androgens a significantly lower risk than other types of ADT [14, 15, 25, 29, 56] . GnRH agonists and antagonists showed a strong association with hepatotoxicity [57] , as did abiraterone acetate, two to three times higher than placebo for men with CRPC [22, 23] .
Reproductive disorders were common with significantly increased risk of gynaecomastia and breast pain for antiandrogens over GnRH agonists [14, 56] . Sexual function was significantly impacted by ADT with only 26% of men expected to retain some sexual function 5 years from initiation of ADT [59] . There was no evidence to suggest a significant difference in relation to type of ADT [15, 25] . The impact of ADT on the risk of depression was confirmed in the systematic review by Nead et al. which showed a 40% higher risk of depression for men receiving ADT which, like sexual function, was associated with exposure [20] . Fatigue is a complex adverse effect associated with many cancer treatments, but for men receiving enzalutamide and abiraterone for PC, there was a 27% greater risk of fatigue and a 50% greater risk for prechemotherapy men initiating ADT [64] . Potentially related to fatigue and other adverse effects, declines in physical function and higher incidence of falls were also associated with ADT, significantly more-so with enzalutamide [69] and apalutamide [49] .
Cognitive disorders were the exception amongst the adverse effect groupings with an inconclusive result from two systematic reviews [16, 26] . Similarly, the systematic review of dementia suggested only that there may be an association between ADT and risk of dementia [19] . Interestingly, McGinty et al. found a statistically significant increased risk associated with visuospatial cognitive skills, suggesting a possible link to increased incidence of falls and fractures for this population [16] .
Such a broad range of adverse effects, some with high levels of incidence, poses problems, not only for the patient and their family who bear the consequences of increased morbidity or mortality and reduced quality of life but also for society. There are significant cost implications of suffering these adverse effects in the form of their management, supportive care and increased health services utilisation, without considerations of productivity losses for those men in this population still actively employed or their carers. Management of adverse effects can take a number of forms from medications or counselling to exercise interventions; each involving increased resource utilisation as well as out of pocket costs for the patient.
In recent years, interest in adverse effects has increased, evidenced by the number of systematic reviews included in this review. There is growing awareness of the impact of many of these adverse effects on the part of clinicians, patients, economists and decision makers, from both a quality of life and a cost perspective. Bourke et al. raised the need for clearly defined adverse effects, in order that a better understanding of potential risks and subsequent treatment costs is developed to accurately inform the costs and effects associated with these drugs [71] . Pearce et al. make a similar point, advising that economic evaluations should include all adverse effects regardless of severity [72] . While the adverse effects associated with ADT are many, varied and complex, it is important that economic evaluations include consideration of them to ensure models are developed that accurately reflect the impact of adverse effects on drug cost-effectiveness, particularly given the current emphasis on personalised care.
No single systematic review has previously provided such a comprehensive review of this topic. This review, conducted and reported following Cochrane guidelines, updates the current knowledge across all common adverse effects of ADT for PC [30] . We employed an a priori designed protocol and carried out an extensive literature search using multiple databases, Google Scholar and bibliographic hand search. Methodological quality of included studies was assessed using three Cochrane approved instruments and, with few exceptions, provided moderate to strong evidence of ADT adverse effects. This systematic review also includes new ADT medications like apalutamide, enzalutamide and abiraterone acetate, and through the weight of recent evidence, confirms effects previously considered contentious, such as cardiovascular toxicity, or rare, such as hepatotoxicity.
This review was limited by available data; while the full range of PC stages from localized to metastatic CRPC were represented, not all types of ADT or all stages of PC were captured for all adverse effects, particularly for newer therapies. Studies were characterised by considerable heterogeneity in study design, aims, outcomes, sample size, exclusion criteria, geographical location, number of sites involved and length of follow-up. While all study participants were men with PC receiving ADT, there was considerable variation between and across studies in relation to age, PC stage, treatment, comorbidities, and demographics. Heterogeneity was not always addressed in meta-analysis. While a rigorous search of the literature was conducted, it is possible that not all studies reporting the adverse effects of ADT for PC were identified.
Conclusion
This review provides the first comprehensive incidence of the most common adverse effects of ADT for PC based on currently available evidence. These findings are significant for clinicians, researchers, health providers, health economists, PC patients, their careers and society. It is evident that more research is needed in adverse effects of ADT for prostate cancer; questions also remain in terms of potential recovery and management. It is hoped this review will assist in stimulating further questions and research around adverse effects, as well as the development of suitable interventions to decrease their risk. These findings also highlight the importance of supportive care for PC patients receiving ADT and their careers. Consideration of adverse effects and their management in economic evaluations of PC treatment is also important, particularly given their potential to add further costs to what is already costly treatment.
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